<div id="readability-page-1"><p>Research analysts at Oppenheimer initiated coverage on shares of <span>ProQR Therapeutics (NASDAQ:PRQR - Get Free Report)</span> in a report issued on Thursday. The brokerage set an &#34;outperform&#34; rating and a $9.00 price target on the biopharmaceutical company's stock. Oppenheimer's target price suggests a potential upside of 409.92% from the company's previous close.</p><div><p><span></span><span>Get <strong>ProQR Therapeutics</strong> alerts:</span></p></div><p>Other analysts also recently issued research reports about the company. Zacks Research upgraded ProQR Therapeutics from a &#34;strong sell&#34; rating to a &#34;hold&#34; rating in a research note on Thursday, November 13th. Weiss Ratings  reaffirmed a &#34;sell (d-)&#34; rating on shares of ProQR Therapeutics in a research report on Thursday, January 22nd. Six research analysts have rated the stock with a Buy rating, one  has assigned  a Hold rating and one  has assigned  a Sell rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of &#34;Moderate Buy&#34; and an average price target of $7.67.</p><p><b>Check Out Our Latest Report on ProQR Therapeutics</b></p><h2>ProQR Therapeutics Stock Performance</h2><p>Shares of NASDAQ:PRQR traded down $0.05 during midday trading on Thursday, hitting $1.77. The company's stock had a trading volume of 54,819 shares, compared to its average volume of 408,578. The stock has a market capitalization of $185.70 million, a price-to-earnings ratio of -3.78 and a beta of 0.21. The stock's 50 day simple moving average is $1.65 and its 200 day simple moving average is $2.07. ProQR Therapeutics has a fifty-two week low of $1.07 and a fifty-two week high of $3.10. </p><h2>Institutional Trading of ProQR Therapeutics</h2><p>A number of hedge funds have recently modified their holdings of PRQR. Privium Fund Management B.V. increased its position in shares of  ProQR Therapeutics by 7.2% during the fourth quarter. Privium Fund Management B.V. now owns 5,357,762 shares of the biopharmaceutical company's stock valued at $10,823,000 after purchasing an additional 359,475 shares during the period.  Affinity Asset Advisors LLC lifted its position in  ProQR Therapeutics by 6.5% in the second quarter. Affinity Asset Advisors LLC now owns 3,499,512 shares of the biopharmaceutical company's stock worth $7,139,000 after purchasing an additional 215,000 shares during the period.  Aberdeen Group plc lifted its position in  ProQR Therapeutics by 28.4% in the fourth quarter. Aberdeen Group plc now owns 2,950,676 shares of the biopharmaceutical company's stock worth $5,960,000 after purchasing an additional 651,853 shares during the period.  Sio Capital Management LLC boosted its stake in  ProQR Therapeutics by 1.0% during the second quarter. Sio Capital Management LLC now owns 2,075,139 shares of the biopharmaceutical company's stock worth $4,233,000 after buying an additional 20,546 shares in the last quarter.  Finally, Ikarian Capital LLC increased its holdings in  ProQR Therapeutics by 67.2% in the 4th quarter. Ikarian Capital LLC now owns 1,492,229 shares of the biopharmaceutical company's stock valued at $3,014,000 after buying an additional 600,000 shares during the period. Institutional investors own  32.65% of the company's stock. </p><h2>ProQR Therapeutics Company Profile</h2> (Get Free Report)<p>ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases. Utilizing its proprietary Axiomer® RNA editing platform, ProQR aims to correct disease-causing mutations directly at the messenger RNA level. The company's pipeline features several investigational candidates, including sepofarsen (formerly QR-110) for Leber congenital amaurosis type 10, QR-421a targeting Usher syndrome and certain forms of retinitis pigmentosa, and QR-313 for dystrophic epidermolysis bullosa.  </p><p>Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR maintains a significant presence in Cambridge, Massachusetts, to support its clinical research and regulatory initiatives.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than ProQR Therapeutics</li><li>How China Accidentally Created Its Own Rare Earth Rival</li><li>Nvidia CEO Issues Bold Tesla Call</li><li>Do this before SpaceX IPOs or be sorry</li><li>The Market Just Split in Two (URGENT)</li><li>Central banks just did something they haven’t done since 1967</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UFJRUg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UFJRUg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in ProQR Therapeutics Right Now?</h2><p>Before you consider ProQR Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ProQR Therapeutics wasn't on the list.</p><p>While ProQR Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

LABD

PRQR

SBIO

<p>Oppenheimer has initiated coverage on ProQR Therapeutics (NASDAQ:PRQR), assigning an "outperform" rating and a price target of $9.00, indicating a potential upside of 409.92% from its previous close. The stock currently trades at $1.77, with an average rating of "Moderate Buy" from analysts. Institutional investors hold 32.65% of the company's shares. ProQR is focused on developing RNA-based therapies for severe genetic diseases, with several investigational candidates in its pipeline.</p>

ProQR Therapeutics (NASDAQ:PRQR) Coverage Initiated at Oppenheimer